Evidence map›Paper›PMID 38383366›Full record

ArticleBMC cancer2024

Prevalence of genital high-risk human papillomavirus infections and associated factors among women living with human immunodeficiency virus in Uganda.

Harriet Nakigozi, Rawlance Ndejjo, William Bazeyo, Annet Nabaggala, Caroline Achola, Moses Iga, Simeon Kalyesubula, Ben Kanamwangi, Gerald Mutungi, Charles Batte and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Harriet NakigoziNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda. harrietnaki@yahoo.com.
Rawlance NdejjoDepartment of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
William BazeyoDepartment of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
Annet NabaggalaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Caroline AcholaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Moses IgaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Simeon KalyesubulaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Ben KanamwangiNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Gerald MutungiDepartment of Non-communicable Diseases, Ministry of Health, Kampala, Uganda.
Charles BatteDepartment of Medicine, Lung Institute, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
David MukunyaFaculty of Health Sciences, Department of Community and Public Health, Busitema University, Mbale, Uganda.
Lawrence SserwangaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Godfrey GemageineNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Charles Akiya OyooDepartment of Non-communicable Diseases, Ministry of Health, Kampala, Uganda.
Susan NabaddaNational Health Laboratory and Diagnostic Services, Ministry of Health, Kampala, Uganda.
Ministry of Health · UGMakerere University · UGBusitema University · UG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen living with HIV are at risk for cervical dysplasia and cancer worldwide. In 2015, the World Health Organization (WHO) recommended that testing for high-risk HPV (hrHPV) infection be incorporated into cervical cancer screening programs using molecular nucleic acid tests (NATs) but this has not previously been done in Uganda. The country's coverage for Human Papilloma Virus (HPV) screening remains low at less than 10% for women aged 25-49 years. This study determined the genital prevalence of hrHPV infection and the associated factors among women living with HIV in Uganda.

methodsA descriptive cross-sectional study was conducted in 15 selected health facilities among participants who were on Antiretroviral therapy (ART). Participants who consented to participate were instructed on how to collect their own high vaginal swabs using a cervical brush for HPV molecular testing (HPV DNA or HPV RNA) and their demographics data was collected using a standard questionnaire. Laboratory diagnosis for HPV molecular testing was done using Gene xpert machines and Hologic Aptima Machine. Modified Poisson regression analysis was conducted to determine the associated factors.

resultsThis study involved 5856 HIV positive participants on ART. A total of 2006 out of 5856 (34.3%) participants had high risk HPV infections. HPV infections by genotypes were: HPV16 317(15.8%), HPV 18/45 308 (15.4%) and other high-risk HPV 1381 (68.8%). The independent factors associated with all hrHPV were parity, education level, having more than one partner, and engaging in early sex. Smoking was associated with HPV 16, HPV 18/45 and other hrHPV. Age was associated with all hrHPV, marital status with HPV 16, and occupation with HPV 16.

conclusionsThe prevalence of genital high-risk HPV infections among HIV positive women attending ART clinics in public facilities in Uganda was high. Other hrHPV genotype was the commonest compared to 18/45 and HPV 16. The integration of cervical cancer screening in ART programmes remains paramount to support the early detection of cervical cancer and Non-invasive self-collected urine and vaginal sampling for cervical cancer screening present an opportunity.

Indexed as

HIV InfectionsPapillomavirus InfectionsSexually Transmitted DiseasesUterine Cervical NeoplasmsCross-Sectional StudiesEarly Detection of CancerFemaleHIVHumansPapillomaviridaePrevalenceUgandaCervical CancerCervical Cancer screeningHologicHPV AptimaHuman immunodeficiency virus (HIV)Human papillomavirus (HPV)PantherPreservecyt solution

Identifiers

PMID38383366
PMCPMC10882885
OpenAlexW4391991682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.